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Bacteriophage‑encoded endolysins degrading the bacterial peptidoglycan are promising antibacterials 
for combating antibiotic‑resistant bacteria. However, endolysins have limited use against Gram‑
negative bacteria, since the outer membrane prevents access to the peptidoglycan. Here, we present 
innolysins, an innovative concept for engineering endolysins to exert antibacterial activity against 
Gram‑negative bacteria. innolysins combine the enzymatic activity of endolysins with the binding 
capacity of phage receptor binding proteins (RBPs). As proof-of-concept, we constructed 12 Innolysins 
by fusing phage T5 endolysin and RBP Pb5 in different configurations. One of these, Innolysin Ec6 
displayed antibacterial activity against Escherichia coli only in the presence of Pb5 receptor FhuA, 
leading to 1.22 ± 0.12 log reduction in cell counts. Accordingly, other bacterial species carrying FhuA 
homologs such as Shigella sonnei and Pseudomonas aeruginosa were sensitive to Innolysin Ec6. To 
enhance the antibacterial activity, we further constructed 228 novel Innolysins by fusing 23 endolysins 
with Pb5. High-throughput screening allowed to select Innolysin Ec21 as the best antibacterial 
candidate, leading to 2.20 ± 0.09 log reduction in E. coli counts. Interestingly, Innolysin Ec21 also 
displayed bactericidal activity against E. coli resistant to third‑generation cephalosporins, reaching a 
3.31 ± 0.53 log reduction in cell counts. Overall, the Innolysin approach expands previous endolysin-
engineering strategies, allowing customization of endolysins by exploiting phage RBPs to specifically 
target Gram‑negative bacteria.
Development of novel antibacterials against Gram-negative bacteria is challenging because they possess an outer 
membrane that prevents many compounds from reaching their intracellular  targets1. Bacteriophages (phages), 
viruses that infect bacteria, have naturally evolved mechanisms to overcome the outer membrane to infect their 
bacterial  hosts2,3. In the first step of infection, phages bind to host cells and inject their genetic material across 
the outer and inner membrane of the bacterial cells into the  cytoplasm4,5. Also, during the final stage of the lytic 
infection cycle, phages produce proteins within the cell, which destroy the bacterial cell wall, leading to cell 
 lysis6,7. Thus, the molecular tools developed during phage evolution may be exploited to develop novel phage-
based antibacterials that are able to pass the outer membrane and to kill Gram-negative bacteria.
Phages recognize their host bacteria by binding to specific surface receptors that may be outer membrane 
proteins, lipopolysaccharides or components of bacterial capsules, pili and  flagella8–10. The adhesion specific-
ity is mediated by receptor binding proteins (RBPs) that form fibers or spikes at the distal phage tail. A well-
characterized RBP is the monomeric Pb5, located at the tail tip of the phage T5, which binds irreversibly to the 
bacterial receptor FhuA during infection of the E. coli  host11,12. FhuA is an outer membrane protein that actively 
transports siderophore-ferrichrome and allows E. coli to take up iron from the environment. The crystal structure 
of FhuA reveals two domains, a 22-stranded anti-parallel barrel and a globular domain, known as the plug. The 
barrel forms a hollow channel containing eleven surface-exposed loops and is blocked by the plug in its inactive 
 state13,14. Pb5 of phage T5 has been shown to have several binding targets on the FhuA, including the L4 loop and 
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the plug of  FhuA15,16. In addition, it was proposed that FhuA acts as an anchor for phage T5 binding to E. coli, 
subsequently allowing the tail fiber composed of Pb2 to transverse the outer membrane and inject the  DNA17.
During the last stage of phage infection, phages produce endolysins to lyse the bacterial cells and release 
progeny phages. Endolysins are enzymes that, after gaining access to the periplasm, degrade the peptidoglycan, 
leading to cell  lysis18. Endolysins may have different catalytic activities, depending on the bond that they target 
in the peptidoglycan, and are classified as glycosidases, amidases or endopeptidases. The endolysin encoded by 
phage T5 is a well characterized endopeptidase that hydrolyzes the bond between L-alanine and D-glutamic 
acid of the peptidoglycan in E. coli19. While native endolysins have been successfully applied as antibacterials 
against Gram-positive bacteria including Staphylococcus aureus and streptococci, the outer membrane of Gram-
negative bacteria generally prevents access to the peptidoglycan  layer20. To enable killing of Gram-negative 
pathogens using endolysins, a number of engineering strategies have been proposed. Recently it was shown that 
the fusion of endolysins with polycationic or amphipathic peptides enabled the engineered endolysins known as 
Artilysins to kill multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii21,22. Furthermore, 
recombinant T4 lysozyme carrying the binding domain of pesticin, targeting the outer membrane protein FyuA, 
killed Yersinia and pathogenic E. coli  strains23. Similarly, fusion of the E. coli phage endolysin Lysep3 with the 
translocation and receptor-binding domain of another bacteriocin, colicin A, targeting the outer membrane 
protein BtuB exerted antibacterial activity against E. coli24. The translocation and receptor-binding domain of P. 
aeruginosa bacteriocin pyocin S2 (PyS2) was also recently fused with GN4 lysin to construct lysocins that could 
kill P. aeruginosa25. Thus, these studies have demonstrated that endolysins can be engineered to overcome the 
outer membrane barrier and subsequently kill Gram-negative bacteria.
Here, we expand on the concept of enabling endolysins to exert antibacterial activity against Gram-negative 
bacteria by exploiting the binding specificity of phage RBPs to bacterial receptors and we develop innovative 
RBP-endolysin hybrids (Innolysins). To provide a proof of concept, we fused the endolysin and the RBP (Pb5) of 
phage T5 to target E. coli (Innolysins Ec). Pb5 was selected among many phage RBPs due to the specific and stable 
binding to its cognate protein receptor, allowing the fused endolysin to exert the antibacterial activity. To expand 
our Innolysin concept, we constructed a library of 228 Innolysins by fusing Pb5 with 23 different endolysins in 
four different configurations. A high-throughput screening for the best antibacterial candidate allowed us to 
select an Innolysin with bactericidal activity against E. coli resistant to critically important antimicrobials such 
as third-generation cephalosporins.
Results
Strategy for construction of innolysins. To construct E. coli-specific Innolysins (Innolysins Ec), we 
combined the RBP of phage T5 (Pb5) with the phage T5 endolysin (T5 Lys) for targeted delivery of the endolysin. 
The binding domain of Pb5 has previously been shown to be located in the N-terminus (488aa) of the  protein26. 
To determine whether the binding domain of the Pb5 was sufficient to enable the endolysin to exert antibacte-
rial activity, we fused T5 endolysin with both the entire Pb5 and with the Pb5 binding domain  (Pb51-488). We 
anticipated that antibacterial activity of an Innolysin Ec requires both that Pb5 is able to bind to the outer mem-
brane protein FhuA, and that the fused phage T5 endolysin remains active to degrade the peptidoglycan. Thus, 
to ensure that the joined domains remain functional after fusion, we either fused them directly or added linkers 
in between. We used flexible linkers composed of small non-polar amino acids, glycine and alanine, providing 
a certain degree of flexibility of the fused  domains27. To optimize the two-domain cooperation, we used linkers 
of two different sizes, L1 composed of six amino acids and L2 that consisted of 14 amino acids. In addition, to 
investigate the optimal orientation of the endolysin and RBP domains, we constructed the Innolysins in two 
directions with and without linkers. As such, a total of 12 Innolysins Ec were initially constructed (Fig. 1).
Figure 1.  Visual representation of construction of Innolysins Ec. Phage T5 endolysin (T5 Lys) was fused with 
the whole phage T5 receptor binding protein, Pb5 or its binding domain  (Pb51-488). Fusion was conducted 
without linkers (Ec1 to Ec4) or with linkers (linker L1: AGA GAG or linker L2: GAG AGA GAG AGA GA) (Ec5 to 
Ec12) with T5 Lys located in the N-terminus (Ec1 and Ec2; Ec5 to Ec8) or in the C-terminus (Ec3 and Ec4; Ec9 
to Ec12) of the engineered endolysins.
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innolysins show muralytic activity. To demonstrate conservation of the muralytic activity of the endoly-
sin after fusion with the RBP and a linker, the fused proteins were expressed in E. coli BL21 and cleared cell 
lysates were tested for muralytic activity. A standardized assay for analysis of the muralytic activity of endolysins 
against Gram-negative bacterial peptidoglycan was used. This assay is based on outer membrane permeabi-
lized P. aeruginosa cells, which share a common peptidoglycan chemotype (Α1γ) with E. coli28. The majority of 
Innolysins (nine out of 12) were active with enzymatic activity ranging between 126–771 U/ml. Innolysin Ec9 
(Pb5-L1-T5Lys) showed the highest activity per ml cleared lysate, which was similar to the muralytic activity of 
phage T5 endolysin alone (795 U/ml) (Fig. 2). Although expression was confirmed for all constructs, three of 
the Innolysins (Ec1, Ec3 and Ec12) and Pb5 alone did not show any significant activity compared to the negative 
control (muralytic activity of cleared cell lysates carrying the empty vector, pVTD). Yet, as expression yield was 
not taken into account, some of these constructs might have muralytic activity. Here, we showed that phage T5 
endolysin fused with Pb5 in different configurations could maintain its muralytic activity.
Innolysin Ec6 inhibits E. coli growth. To assess whether binding of Pb5 allowed the fused endolysin to 
exert antibacterial activity, we screened the muralytically active Innolysins for their ability to inhibit growth of 
the phage T5 bacterial host E. coli ATCC11303. This strain was mixed with cleared lysates of cells expressing 
Innolysins, and bacterial growth was measured spectrophotometrically after 18 h at 37 °C (Fig. 3). Growth inhi-
bition was determined as the lack of growth of a start inoculum treated with an Innolysin compared to growth 
of ATCC11303 cells treated with cleared lysates of cells carrying the empty vector, pVTD (negative control). 
When E. coli ATCC11303 was treated with Innolysin Ec6 a significant inhibitory activity was noticed, which 
was similar to that of Art-175, an engineered endolysin that was previously shown to have both an inhibitory 
and bactericidal effect against various E. coli  isolates29,30. The remaining eight Innolysins, Pb5 or endolysin alone 
did not significantly affect the E. coli growth compared to the negative control (Fig. 3). Out of the 12 initially 
constructed Innolysins, this screening resulted in one promising antibacterial candidate that could inhibit E. coli 
growth, indicating that domains may have to be fused in a specific order and with a specific linker to acquire 
antibacterial activity after fusion. However, we could not exclude that a potential antibacterial candidate might 
not have been identified during our screen due to low protein expression yield. The active variant Ec6 was 
composed of T5 endolysin in the N-terminus linked by a six amino-acid linker to  Pb51-488 in the C-terminus. 
This result demonstrates that the binding domain of Pb5 is able to target the bacterial cells, allowing phage T5 
endolysin to inhibit E. coli growth.
Antibacterial activity of Innolysin Ec6 requires FhuA, but not TonB-provided energy. To 
determine whether FhuA is required for the antibacterial activity of Innolysin Ec6, the purified hybrid pro-
tein was tested on a fhuA deletion mutant of E. coli BL21 and compared to the wild type E. coli BL21 and 
E. coli ATCC11303. Bacterial cells were incubated with the purified Innolysin Ec6 at a final concentration of 
0.2 mg/ml and the reduction in cell counts was compared to the cells treated with 20 mM HEPES–NaOH, as a 
negative control (Fig. 4). E. coli BL21 cell counts were reduced by 1.22 ± 0.12 log after 30 min of treatment with 
Innolysin and a similar decrease was noticed for E. coli ATCC11303 cells (1.09 ± 0.15 log reduction). In contrast, 
treatment of E. coli BL21 with either T5 endolysin or  Pb51-488 did not significantly reduce the cells, leading to 
0.07 ± 0.06 and 0.01 ± 0.01 log reductions, respectively. No significant effect of the Innolysin was shown against 
E. coli BL21ΔfhuA, supporting our hypothesis that the Innolysin exerts antibacterial activity only when cells 
Figure 2.  Muralytic activity of Innolysins Ec. Cleared lysates of the Innolysins Ec1-Ec12 (see Fig. 1) were 
screened for ability to degrade peptidoglycan of P. aeruginosa PAO1 compared to the activity of cleared lysates 
of cells carrying the empty vector, pVTD (negative control). Phage T5 endolysin (T5 Lys) and receptor binding 
protein (Pb5) were used as a positive and a negative control, respectively. Average muralytic activities (U/ml 
cleared lysate) were estimated based on triplicates. *Significant muralytic activity compared to the negative 
control (cleared lysate of cells carrying the empty vector, pVTD) at P < 0.05.
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harbor the Pb5 receptor, FhuA. FhuA uptake of ferrichrome requires energy from the cytoplasmic proton motive 
force transduced to the outer membrane via the TonB protein, but phage T5 interacts with FhuA independent of 
 TonB14,31. To determine whether activity of Innolysin Ec6 required such energy, antibacterial activity was tested 
against an E. coli tonB deletion mutant (ECOR4ΔtonB) and the wild type ECOR4 as a positive control (Fig. 4). 
Approximately 1 log reduction was demonstrated in both ECOR4ΔtonB and the wild type ECOR4 in cell num-
bers after 30 min of treatment with Innolysin Ec6 (Fig. 4), supporting that TonB was not required for Innolysin 
to work as an antibacterial. Our combined data demonstrate that Innolysin Ec6 requires the presence of FhuA 
but not TonB-provided energy to exert antibacterial activity.
Figure 3.  Growth of E. coli after treatment with Innolysins Ec. Cleared fractions of muralytically active 
engineered proteins (see Fig. 2) were screened for the ability to inhibit growth of E. coli ATCC11303. Art-
175 was provided by Lysando  AG29 and used as a positive control. Phage T5 endolysin (T5 Lys) and receptor 
binding protein (Pb5) were used as negative controls. Growth inhibition was detected as the absence of growth 
 (OD655nm) of cells treated with an Innolysin in comparison to the negative control (growth of ATCC11303 
cells treated with cleared lysate of cells carrying the empty vector, pVTD) after incubation for 18 h at 37 °C. 
*Significant bacterial growth inhibition at P < 0.05.
Figure 4.  Antibacterial activity of Innolysin Ec6 and Ec21 against E. coli. Average logarithmic reductions in 
the cell counts of different E. coli strains, after incubation with 0.2 mg/ml either of Innolysin Ec6 or of Ec21 for 
30 min at 20 °C, compared to the cells treated with 20 mM HEPES–NaOH as a negative control. The average 
reduction was calculated based on triplicates of three independent experiments. *Significant reduction at 
P < 0.05.
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Morphological changes of cells treated with Innolysin Ec6. Transmission electron microscopy 
(TEM) analysis was performed to determine the effects of Innolysin Ec6 on cell morphology and viability. The 
morphology of both E. coli BL21 and E. coli BL21ΔfhuA was visualized after incubation with 0.2 mg/ml Innoly-
sin Ec6 for 15 min and compared to cells treated with 20 mM HEPES–NaOH (pH 7.4) as a negative control 
(Fig. 5). Almost all cells treated with HEPES–NaOH were intact with normal cell envelope morphology. In con-
trast, treatment of E. coli BL21 with Innolysin Ec6 led to cell integrity damage in the majority of cells with cytosol 
leakage occurring mainly at the poles. Furthermore, cell debris could be detected possibly due to cell lysis. This 
dramatic effect on cell morphology was not observed on E. coli BL21ΔfhuA treated with Innolysin Ec6, where 
only a few damaged cells were noticed compared to the cells treated with HEPES–NaOH. These observations 
demonstrate that Innolysin Ec6 acts rapidly by interfering with membrane integrity and reconfirms that the 
presence of FhuA is essential for Innolysin Ec6 to exert high antibacterial activity.
Innolysin Ec6 targets FhuA homologs of species other than E. coli. To investigate whether the 
constructed Innolysin Ec6 could target FhuA homologs in other species, we tested the antibacterial activity of 
the purified Innolysin against Shigella sonnei and Pseudomonas aeruginosa (Fig. 6). These bacteria carry FhuA 
homologs with identity to the FhuA of E. coli BL21 ranging between 22.6 and 99.6% (Supplementary Table S1). 
The Innolysin displayed antibacterial activity against S. sonnei (99.6% FhuA identity) and P. aeruginosa PAO1 
(less than 39% of overall FhuA identity), leading to average log reductions in cell number of 1.52 ± 0.14 and 
1.03 ± 0.25, respectively. To give support that the antibacterial activity of Innolysin Ec6 against the tested strains 
is specific for the Innolysin, we further tested the antibacterial activity of either T5 endolysin or the Pb5 1–488. 
Treatment with T5 endolysin did not significantly reduce the cell counts of either P. aeruginosa (0.08 ± 0.02 log 
Figure 5.  Morphological changes of E. coli treated with Innolysin Ec6. The effect of Innolysin Ec6 on BL21 
(B–D) and BL21ΔfhuA (F) was compared to the BL21 treated with 20 mM HEPES–NaOH (A) and BL21ΔfhuA 
(E), respectively. Cytosol leakage mainly at poles (B, arrow 1); cell debris likely due to cell lysis (C, arrow 2) 
and increased transparency in the periphery of cells (D, arrow 3 & 4) were observed in the majority of BL21 
cells treated with the Innolysin. Such dramatic changes were not observed in BL21ΔfhuA cells after incubation 
with Innolysin Ec6 (F). Images were recorded on a side-mounted Olympus Veleta (2048 × 2048 pixels) charge-
coupled device camera via the iTEM software (Olympus SIS, Muenster, Germany), version 5.1 (Build 2,108), 
Microsoft Windows NT 5.1 (Build 2,600) Service Pack 3 2.097.151 KB total memory (https ://cfim.ku.dk/equip 
ment/elect ron_micro scopy /cm100 /iTEM_Main_Broch ure.pdf).
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reduction) or S. sonnei, (0.09 ± 0.04 log reduction). Similarly,  Pb51-488 did not display significant antibacterial 
activity against both strains, leading to 0.04 ± 0.03 and 0.07 ± 0.05 log reduction of the cells, respectively. There-
fore, we conclude that Innolysin can target FhuA homologs in species other than E. coli and exert antibacterial 
activity.
enhanced innolysins with activity against E. coli resistant to third‑generation cephalospor‑
ins. To further explore the Innolysin concept, we constructed a library comprising 228 novel Innolysins by 
fusing one out of 23 different endolysins (Supplementary Table S2) with Pb5 or  Pb51-488 in four configurations (as 
described in the supplementary method and Fig. S1). To identify Innolysins with high antibacterial activity, we 
initially used a high-throughput growth inhibitory assay on E. coli BL21 and screened the library in a redundant 
way by analyzing 380 variants (i.e., 95 variants from each configuration). We selected 12 Innolysins showing the 
strongest growth inhibition for each configuration (Supplementary Table S3 and S4). Of these 48 Innolysins, 32 
were confirmed to be muralytically active (Supplementary Fig. S2) and could significantly inhibit the E. coli BL21 
growth based on three independent experiments (Supplementary Fig. S3). Interestingly, Innolysins belonging to 
all four configurations could inhibit E. coli BL21 growth with Innolysin Ec21 demonstrating the highest growth 
inhibition effect. Innolysin Ec21 was composed of endolysin LysEC8 fused in its C-terminus with  Pb51-488 by a 
flexible linker (Supplementary Table S4). To assess whether LysEc8 alone could exert antibacterial activity, the 
killing efficiency of LysEc8 was tested against E. coli BL21. No significant effect on the cell numbers was detected 
with log reduction reaching to 0.08 ± 0.07. In contrast, application of purified Innolysin Ec21 (0.2 mg/ml) on E. 
coli BL21 led to 2.20 ± 0.09 log reduction in cell numbers, thus increasing the antibacterial activity compared to 
Innolysin Ec6 that led to 1.22 ± 0.12 log reduction (Fig. 4). To determine whether Innolysin Ec21 was also effec-
tive against antibiotic-resistant E. coli strains, the antibacterial activity was tested against six E. coli resistant to 
third-generation cephalosporins isolated from production animals and meat (Supplementary Table S5). Inter-
estingly, three out of the six of such E. coli strains were sensitive to Innolysin Ec21 with the maximum bacteri-
cidal activity reaching to 3.31 ± 0.53 log reduction in cell number (Fig. 4). In contrast, no reduction of cell counts 
was observed when the remaining three E. coli strains were treated with Innolysin Ec21, displaying resistance. 
Therefore, our results indicate a variable sensitivity of antibiotic-resistant E. coli resistant to third-generation 
cephalosporins to Innolysin Ec21.
To understand the variability in antibacterial spectrum of the E. coli strains tested, we investigated whether the 
sensitivity pattern correlates with differences in the FhuA protein sequence, potentially affecting the interaction 
and activity of Innolysin Ec21. Alignment of the FhuA protein sequences showed that Innolysin sensitivity was 
not correlated with the presence of specific loops of the FhuA barrel, including the L4 loop previously shown to 
be one of the binding targets of phage T5  Pb515,17. Some sensitive strains even lacked the amino acids responsible 
for the formation of L4 loop in FhuA (Fig. 7), suggesting that the L4 loop is not required for the antibacterial 
activity of Pb5-based Innolysins. In addition, sequence variation was observed in other FhuA regions between 
strains, but with no correlation to the sensitivity profile. Thus, variations in FhuA cannot explain the Innolysin 
Ec21 killing spectrum of antibiotic-resistant E. coli. Overall, by shuffling endolysin components we enhanced 
Figure 6.  Antibacterial spectrum of Innolysin Ec6. Average logarithmic reductions of different species in cell 
numbers, after incubation with 0.2 mg/ml Innolysin Ec6 for 30 min at 20 °C, compared to the cells treated with 
20 mM HEPES–NaOH as a negative control. The data represent the average of three biological triplicates with 
three technical replicates each. * Significant reduction at P < 0.05.
7Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12087  | https://doi.org/10.1038/s41598-020-68983-3
www.nature.com/scientificreports/
the antibacterial activity of Innolysins and showed that Innolysins can be used as antibacterials to kill at least a 
subset of antibiotic-resistant E. coli.
Discussion
Phages have developed unique and complex mechanisms to infect and lyse bacteria. In the first stage of infection, 
phages utilize RBPs to target specific bacterial host receptors on the cell surface, whereas at later stages phage 
endolysins degrade peptidoglycan, inducing lysis and progeny release. Here, we exploited the binding capacity 
of a phage RBPs to enable an endolysin to exert antibacterial activity. As proof of concept, we used the phage 
T5 endolysin and its RBP Pb5 and constructed 12 Innolysins by fusing the endolysin to the whole Pb5 or the 
binding domain of Pb5 in different orientations, with or without linkers. The majority of the novel Innolysins 
maintained their muralytic activity and Innolysin Ec6 also reduced the E. coli cell viability by approximately 1 log. 
To improve the antibacterial activity of Innolysins, we redundantly screened a library of 228 novel Innolysins each 
consisting of one out of 23 different endolysins fused with Pb5 in four distinct configurations. Growth inhibition 
was obtained for Innolysins from all four classes, indicating that Pb5 could be fused with different endolysins 
in several configurations and still could enable the fused endolysins to exert antibacterial activity. Interestingly, 
high-throughput screening for the best antibacterial candidate allowed the identification of Innolysin Ec21, 
that increased the reduction of E. coli cells compared to Innolysin Ec6, reaching to approximately 2 log. The two 
Innolysins share the same configuration (endolysin-Linker 2-Pb51-488), but differ in the endolysin component, 
as Innolysin Ec6 and Ec21 contain phage T5 endolysin and LysEC8, respectively.
Here we showed that neither the cell viability nor the morphology of BL21ΔfhuA cells was changed after 
application of Innolysin Ec6, indicating that antibacterial activity of the Innolysin is dependent on the presence 
of the phage T5 receptor,  FhuA11,12. Since FhuA functions as a transport channel for uptake of ferrichrome, 
it is tempting to speculate that an Innolysin might be transported through the channel. Yet, it has previously 
been shown that Pb5 binding to FhuA did not open the  channel11,15. Furthermore, our results demonstrate that 
Innolysin Ec6 activity is independent of energy provided by TonB, which is needed for the opening of the channel. 
Figure 7.  Alignment of E. coli BL21 FhuA with homologous proteins of E. coli resistant to third-generation 
cephalosporins. E. coli BL21 FhuA (WP_000124402.1) was aligned to either FhuA or Ferrichrome Iron 
Receptors (FIR) of ESBL-producing E. coli strains (702: FIR (ESC_RA7174AA_AS_04180); 708: FIR (ESC_
RA7666AA_AS_01170); 723: FhuA (ESC_RA7193AA_AS_00052); 724: FhuA (ESC_RA7194AA_AS_03122); 
728: FhuA (ESC_RA7198AA_AS_01051); 770: FIR (ESC_RA7701AA_AS_01976)). Amino acids are colored 
based on the level of conservation with transition from light to dark grey to represent increasing conservation. 
Conservation with no threshold was used when we used the Jalview sequence alignment tool. The box highlights 
the alignment in the region responsible for the formation of the surface-exposed part of loop L4 in E. coli BL21.
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Therefore, binding of an Innolysin might not provide the conformational changes, leading to the opening of FhuA 
channel. In addition, the size of the unplugged channel (2.5 nm)13,14 appeared to be too narrow for Innolysin 
Ec6 (67.62 kDa) to  pass32, similarly to what was previously suggested for a hybrid lysin consisting of the phage 
T4 lysozyme and the binding domain of pesticin targeting  FyuA19. Thus, we hypothesize that Innolysins might 
overcome the outer membrane barrier by other means than passing through the FhuA channel.
One possible way that Innolysins could access the peptidoglycan might be by interfering with the membrane 
integrity. FhuA has been proposed to function as an anchor for phage T5 by an irreversible binding of Pb5 to 
the FhuA  receptor15,17. We combined Pb5 with phage T5 endolysin, which is a globular endolysin carrying a 
single enzymatically active domain (EAD) with limited intrinsic antibacterial  activity33. By irreversible binding 
to  FhuA11, Pb5 might bring the Innolysin in close proximity to the outer membrane. Therefore, the Innolysin 
could interfere with phosphates in the outer membrane lipopolysaccharides and displace the stabilizing  Mg2+/
Ca2+ ions due to the basic isoelectric point of phage T5 endolysin (7.91), thus destabilizing the ionic forces in 
the outer  membrane34. Outer membrane interference has also been described for Artilysins, endolysins engi-
neered with polycationic or amphipathic peptides that destabilize the outer membrane and target the endolysins 
to  peptidoglycan21. Similar to polycationic peptides, the positively charged N-terminal extension of Thermus 
phage 2,631 endolysin has been shown to be crucial for the enzyme to pass through the outer membrane and 
exert a strong antibacterial activity against Gram-negative  bacteria35,36. This mode of action could also explain 
how substituting the T5 endolysin by other endolysin components with higher pI resulted in an increase of the 
antibacterial activity of Innolysin Ec21. LysEC8 endolysin, the endolysin component in Innolysin Ec21, displays 
a pI of 9.16 exceeding the T5 endolysin pI (7.91). This difference might influence the distribution of ions in the 
surrounding interfacial region, thereby destabilizing outer membrane ionic interactions more efficiently. Interest-
ingly, we noticed that Innolysin Ec6 caused cytosol leakage mainly from the bacterial poles of the wild type E. coli 
carrying the FhuA. It has been shown that several phages preferentially adsorb at the bacterial poles, including E. 
coli phage φ80 that uses FhuA as  receptor37. Therefore, Innolysins may bind to the bacterial surface in a similar 
manner as phages and interfere locally with the outer membrane integrity to allow the fused endolysins to target 
peptidoglycan. However, further insights in the exact mechanism by which the RBPs enable the fused endolysins 
to exert antibacterial activity are needed to clarify the mode of Innolysins action.
Interestingly, Innolysin Ec21 demonstrated bactericidal activity against three out of six tested E coli strains 
resistant to third-generation cephalosporins with killing efficiency reaching to 3.31 ± 0.53 log reduction in only 
30 min. This diverse killing spectrum of Innolysin Ec21 could not be explained by differences in the binding 
ability of the Innolysin to FhuA since killing abilities were not correlated with differences in the FhuA protein 
sequence, including the L4 loop that is one of the binding targets of phage  T531,38. Therefore, other mechanisms 
such as receptor masking by lipopolysaccharides (LPS) or downregulation of receptor  expression39,40 could play 
a role in Innolysin resistance. Furthermore, if Innolysins indeed interfere with the ionic interactions, differences 
in LPS composition could affect membrane integrity and could explain the variation in sensitivity to Innolysins 
similarly. Therefore, the killing efficiency of an Innolysin might be affected not only by the endolysin component 
but also by the outer membrane composition of the specific strain.
In this study, we used the binding specificity of the phage T5 RBP to its cognate FhuA receptor to enable an 
endolysin to exert antibacterial activity. FhuA is conserved in bacterial species, including Escherichia and Shigella, 
and is structurally homologous to other TonB-dependent outer membrane receptors involved in bacterial iron 
 uptake41. Our results demonstrate that Innolysin Ec6, similar to bacteriocin-derived fusions with endolysins, 
can target isolates of bacterial species other than Escherichia coli, including Shigella sonnei and Pseudomonas 
aeruginosa. As opposed to some bacteriocins and traditional antibiotics targeting outer membrane  proteins42, 
Innolysins exert antibacterial activity against Gram-negative bacteria independent of the energy provided by 
TonB. These results give support to the potential of using Innolysins against non-actively growing bacteria. 
Similar to antibiotics, it is expected that bacterial resistance to Innolysins may emerge, putatively by mutations 
on the binding targets of Innolysins. Yet, some mutations of receptors targeted by phages are known to affect the 
bacterial virulence. In the case of Innolysins Ec, mutations in FhuA may not be critical for the bacterial virulence 
because E. coli use at least seven iron acquisition  systems43. However, having provided the proof of concept will 
now allow us to use the vast diversity of phage RBPs to design Innolysins able to target outer membrane struc-
tures that constitute virulence determinants such as OmpX in Escherichia coli and Ail in Yersinia pestis44,45. In 
summary, we have demonstrated a novel antibacterial concept and have shown the potential for optimization of 
Innolysins activity by shuffling. In future, this concept may be further expanded to target other Gram-negative 
bacteria exploiting phage RBPs binding specificity and the vast diversity of bacterial receptors.
Materials and methods
Bacterial strains. E. coli BL21(DE3) CodonPlus-RIL (Agilent Technologies) was used for expression of 
recombinant proteins. Inhibition assays were conducted with E. coli ATCC11303 (Leibniz Institute) and E. coli 
BL21(DE3) (Agilent Technologies). E. coli ECOR4 (STEC Center at Michigan State University), Shigella son-
nei46 and Pseudomonas aeruginosa  PAO147 were also used for antibacterial activity of Innolysin Ec6. Deletions 
of the fhuA and tonB genes on the chromosomes of E. coli BL21(DE3) and E. coli ECOR4, respectively, were 
previously generated by the Lambda red recombination system as described  before48. Antibacterial activity of 
Innolysin Ec21 was tested against six E. coli strains resistant to third-generation cephalosporins collected during 
surveillance of antibiotic resistance in indicator E. coli from production animals and food in Denmark. These 
E. coli strains exhibit an AmpC phenotype due to promoter mutations leading to upregulation of the chromo-
somal ampC and belong to different sequence types (ST-types) by Multi Locus Sequence Typing (Supplementary 
Table S5).
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cloning of constructs. Linker L1 (AGA GAG ) or linker L2 (GAG AGA GAG AGA GA) were used for joining 
the coding sequences of Pb5 and the endolysins, whereas a His-tag was fused to the C-terminus of all constructs. 
Cloning of DNA fragments encoding endolysins, linkers and His-tag and their assembly to Innolysin encoding 
sequences was conducted as described  elsewhere49,50. In brief, genomic material was purified from phage T5 
(Leibniz Institute) and used as a template for amplification (Pfu polymerase; Thermo Fisher Scientific, Waltham, 
MA) of the genes encoding T5 endolysin (YP_006868.1) or Pb5 (YP_006985.1) with specific primers (Sup-
plementary Table S6). The amplified DNA fragments were separately cloned into the pVTE vector by conduct-
ing 30 cycles of restriction with 10 U SapI type IIs restriction enzyme (37 °C, 2 min) and ligation with 3U T4 
DNA ligase (16 °C, 3 min), followed by transformation of E. coli TOP10. Transformed cells were selected on LB 
(Lysogeny Broth) agar plates in the presence of ampicillin (100 μg/ml) and supplemented with 5% sucrose as a 
positive selection for recombinants. Subsequently, these pVTE plasmids were extracted and used for assembly 
of the different DNA fragments (50 ng/µl of each pVTE vector) into the concatenated sequence encoding an 
Innolysin. This assembly and the insertion into destination vector pVTD was done using 10U BsaI and 3U T4 
DNA ligase and the same cyclic reaction as above. The assembly reaction mixture was used for transformation 
of E. coli BL21(DE3)-CodonPlus RIL cells by heat shock. Transformant cells were plated on LB agar plates sup-
plemented with kanamycin (100 μg/ml) and chloramphenicol (50 μg/ml).
Protein expression and purification. For the library screening, 95 single colonies were randomly picked 
up from each configuration for downstream analysis. Freshly transformed colonies were resuspended in 500 μl 
of auto-induction medium (93% ZY medium, 0.05% 2 M  MgSO4, 2% 50 × 5,052, 5% 20 × NPS) in a 96 deep-
well plate and incubated at 37 °C for 5 h, followed by 16 °C for 40 h, both at 900 rpm. Cells were spun down by 
centrifugation (3,200 × g, 30 min, 4 °C) and the supernatants were removed. Cell pellets were lysed by exposure 
to chloroform vapor, by placing the deep-well plate upside-down in a glass petri dish containing chloroform-
saturated filters for 2 h. Cell lysates were resuspended in 20 mM HEPES–NaOH (pH 7.4), and 1 U DNase I, fol-
lowed by incubation (100 × rpm, 1 h, 30 °C). The lysates were investigated by SDS-PAGE analysis to confirm the 
protein expression, but protein yield could not be accurately quantified. Insoluble fractions of cell lysates were 
removed by centrifugation (3,200 × g for 30 min, at 4 °C) and the cleared lysates were screened for both muralytic 
and inhibitory activities.
For large-scale expression of the Innolysin Ec6 and Ec21, a 1 L expression culture (LB medium) was induced 
with 1 mM isopropyl-beta-D-thiogalactopyranoside (Thermo Fisher Scientific) in the mid-logarithmic phase 
 (OD600 = 0.6). Incubation of the culture was performed at 16 °C for 18 h at 120 rpm. Cells were harvested by 
centrifugation (8,000 × g, 10 min, 4 °C) and the cell pellet was resuspended in 10 ml of lysis buffer (20 mM 
 NaH2PO4-NaOH, 0.5 M NaCl, 50 mM imidazole, pH 7.4), followed by sonication (Bandelin Sonopul HD 2070 
homogeniser) with 10 bursts of 30 s (amplitude of 50%) with 30 s intervals. Protein lysate was double-filtered 
using filters with pore size of 0.22 μm. His GraviTrap™ gravity flow columns (GE Healthcare) were used for 
His-tagged protein purification according to the manufacturer’s instructions. Buffer exchange was performed 
against 20 mM HEPES–NaOH (pH 7.4) by using  AmiconR Ultra—4 centrifugal filters with 50 kDa cutoff (Merck 
Millipore) and protein concentration was measured by Qubit™ Protein Assay Kit (Q33211) with a Qubit 2.0 
Fluorometer (Invitrogen, Q32866).
Muralytic assay. Analysis of the muralytic activity was conducted as described  before21,51 using outer mem-
brane permeabilized P. aeruginosa PAO1 cells as substrate. Briefly, exponentially growing cells  (OD600 = 0.6) were 
harvested by centrifugation (3,200 × g, 30 min, 4 °C) and permeabilized by resuspension in chloroform-saturated 
0.05 M Tris–HCl (pH 7.7) and gentle shaking for 45 min. To remove chloroform traces, cells were washed twice 
with phosphate-buffered saline (PBS, pH 7.4) and further concentrated to  OD600 = 1.5. 30 μl of the cleared lysates 
was added on top of 270 μl of the substrate. Cleared lysates of cells expressing the phage T5 endolysin or carrying 
an empty vector (pVTD) were used as positive and negative controls, respectively. Turbidities were measured 
spectrophotometrically at 655 nm every 30 s for one hour by a Microplate Reader 680 system (Bio-Rad). Mura-
lytic activities were calculated by a previously described standardized  method52.
Growth inhibition assay. E. coli cells were used for the growth inhibition assay. Overnight cell cultures 
prepared in Mueller Hinton (MH) broth were adjusted to  OD600 = 0.1 in 2×MH and further 100-fold diluted in 
2×MH. 50 µl of the cell suspension was mixed with 50 μl of the soluble lysate fraction. Art-175 (0.1 mg/ml) and 
the soluble lysate fraction of cells carrying an empty vector pVTD were mixed with cells as positive and negative 
controls, respectively. Endpoint measurement was performed spectrophotometrically at 655 nm after exactly 
18 h incubation at 37 °C. All experiments were done in biological triplicate.
Antibacterial assay. Overnight cultures of E. coli strains were subcultured in LB and supplemented with 
2 μg/ ml cefotaxime in case of the E. coli strains resistant to third-generation cephalosporins. Cells were grown 
exponentially  (OD600 = 0.6) and 100-fold diluted in 20 mM HEPES–NaOH (pH 7.4). 100 μl of the diluted cell 
suspensions were mixed with 100 μl of the pure Innolysin at a final concentration of 0.2 mg/ml. 100 μl of 20 mM 
HEPES–NaOH (pH 7.4) was added to the cells as a negative control. The samples were incubated for 30 min at 
20 °C, and appropriate cell dilutions were plated in triplicate on LB agar plates, with 2 μg/ ml cefotaxime in case 
of E. coli strains resistant to third-generation cephalosporins. After overnight incubation at 37 °C, colony form-
ing units (CFU) were counted and cell concentrations (CFU/ml) were calculated. Experiments were conducted 
three independent times. The antibacterial activity was determined based on the difference of the average loga-
rithmic cell concentrations of the Innolysin treated samples compared to the negative control.
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transmission electron microscopy. Exponentially growing cells (1 ml) were harvested by centrifuga-
tion (10,000 rpm, 5 min) and resuspended in 200 μl of 20 mM HEPES–NaOH (pH 7.4). This washing pro-
cedure was repeated 3 times, after which the cell pellets were resuspended in either 50 μl of HEPES buffer or 
the Innolysin Ec6 and incubated for 15 min at 20 °C. Samples were negatively stained with 2% uranyl-acetate 
on glow-discharged continuous carbon-coated 300-mesh copper grids (EM Resolutions Ltd). Transmission 
electron microscopy was performed on a Philips CM100 (Tungsten emitter) electron microscope operating at 
100 kV. Images were recorded on a side-mounted Olympus Veleta (2048 × 2048 pixels) charge-coupled device 
camera via the iTEM software (Olympus SIS, Muenster, Germany).
Bioinformatic analysis. To identify FhuA homologs, we used the FhuA protein sequence of E. coli BL21 
(WP_000124402.1) to search homologous proteins in the National Center for Biotechnology Information 
(NCBI) genome database through  BLASTP53. Homologous proteins with different levels of identity in species 
other than E. coli were selected and aligned by the multiple sequence alignment tool Clustal  Omega54, through 
which the percent identity was obtained (Supplementary Table S1). Clustal Omega was also used to align FhuA 
or Ferrichrome Iron Receptor (FIR) protein sequences obtained by in silico analysis of ESBL-producing E. coli 
strains (702: FIR (ESC_RA7174AA_AS_04180); 708: FIR (ESC_RA7666AA_AS_01170); 723: FhuA (ESC_
RA7193AA_AS_00052); 724: FhuA (ESC_RA7194AA_AS_03122); 728: FhuA (ESC_RA7198AA_AS_01051); 
770: FIR (ESC_RA7701AA_AS_01976), using the protein sequence of E. coli BL21 FhuA (WP_000124402.1) 
as a reference. To further illustrate the conserved regions of the proteins (Fig. 7) we used the Jalview sequence 
alignment  tool55.
Statistical analysis. Analysis of the data was conducted by using GraphPad Prism 7 software (Version 
7.0d). For muralytic assays, the activity of each cleared lysate of cells expressing Innolysins was tested in triplicate 
and means of activity was compared with the average activity of the cleared lysates of cells carrying the empty 
vector. The significance of the difference in muralytic activity was assessed with Unpaired-Samples t-test using 
95% confidence interval for the mean difference. The same software and also the same statistical test was used to 
analyze results from the growth inhibition assays, using the optical density  (OD655) of the bacterial growth after 
incubation with the cleared lysate of each protein compared to the optical density of cells grown after treatment 
with the cleared lysate of cells carrying the empty vector. For the antibacterial assay, all bacterial counts were 
converted to log-scale and means, and standard deviations were calculated afterwards. Antibacterial activity 
was tested in triplicate in three independent experiments. Decimal reductions of cells were calculated by the 
difference between the average logarithmic concentrations of cells treated with Innolysin and cells treated with 
20 mM HEPES–NaOH (pH 7.4) as a negative control. The significance of the decimal reductions of cells was 
assessed with Paired-Samples t-test using 95% confidence interval percentage.
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